Oregon § 441.068 Hospital policies and procedures for dispensing HIV post-exposure prophylaxis drugs or therapies

Oregon Statutes

§ 441.068 — Hospital policies and procedures for dispensing HIV post-exposure prophylaxis drugs or therapies

Oregon § 441.068

Vol.12

Title 36Public Health and Safety

Ch. 441Health Care Facilities

This text of Oregon § 441.068 (Hospital policies and procedures for dispensing HIV post-exposure prophylaxis drugs or therapies) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 441.068 (2026).

Text

(1)As used in this section, “hospital” has the meaning given that term in ORS 442.015, excluding special inpatient care facilities as defined by the Oregon Health Authority by rule.

(2)A hospital licensed under ORS 441.025 must:

(a)Adopt a policy for the dispensing of human immunodeficiency virus post-exposure prophylaxis drugs or therapies; and

(b)Have procedures in place to ensure that hospital staff dispense to a patient, with a patient’s informed consent, at least a five-day supply of human immunodeficiency virus post-exposure prophylactic drugs or therapies following the patient’s possible exposure to human immunodeficiency virus, unless medically contraindicated.

(3)The hospital policy adopted under this section must in all respects, other than as specified in subsection (2) of

Free access — add to your briefcase to read the full text and ask questions with AI

(1) As used in this section, “hospital” has the meaning given that term in ORS 442.015, excluding special inpatient care facilities as defined by the Oregon Health Authority by rule.
(2) A hospital licensed under ORS 441.025 must:
(a) Adopt a policy for the dispensing of human immunodeficiency virus post-exposure prophylaxis drugs or therapies; and
(b) Have procedures in place to ensure that hospital staff dispense to a patient, with a patient’s informed consent, at least a five-day supply of human immunodeficiency virus post-exposure prophylactic drugs or therapies following the patient’s possible exposure to human immunodeficiency virus, unless medically contraindicated.
(3) The hospital policy adopted under this section must in all respects, other than as specified in subsection (2) of this section, conform to guidelines issued by the Centers for Disease Control and Prevention.